In OlympiAD study (34), Olaparib significantly prolonged progression-free survival (PFS) of patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer compared to chemotherapy (7.0 months vs. 4.2 months). This evidence concerns the gene ERBB2 and breast carcinoma.